Skip to main content

Table 5 Comparison of adverse events between cisplatin combined with IL-2 versus cisplatin alone

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Study Study size (N) Myelotoxicity Nausea/vomiting Chest pain Fever
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Group 1 Group 2 N % N % N % N % N % N % N % N %
Changjie H 2001 [15] 30 30 13 43.3 0 0 10 33.3 0 0
Xiuzhi Y 2001 [16] 40 20 14 35 11 55 5 12.5 5 25
Zhuo S 2004 [17] 32 30 3 9.3 3 10 5 15.6 4 13.3
Junyan W 2005 [18] 48 34 12 25 8 23.5 18 37.5 11 32.4
Haiying X 2009 [19] 35 28 3 9 8 28.6 8 22.9 9 32.1 12 36.4 1 4
Xiaoxia H 2009 [20] 37 35 13 35.1 10 25 11 29.7 11 31.4 4 10.8 3 8.6
Lizheng C 2009 [21] 46 40 12 26.1 4 10
Jinguang C 2009 [22] 31 31 6 20 8 26 5 16 3 10 6 19 2 6
Junfeng W 2010 [23] 41 41 19 46.4 21 51.2 6 14.6 8 19.5 21 51.2 15 36.3
Jingping Z 2010 [24] 63 61 4 6.3 3 4.9 7 11.1 2 3.3 12 19.5 9 14.8 13 20.6 4 6.6
Cheng X 2010 [25] 41 41 6 19.4 8 25.8 11 35.5 7 26.6 7 22.6 4 12.9 9 29 7 26.6
Fang S 2011 [26] 30 30 2 6.6 3 10 4 13.3 6 20 7 23.3 5 16.6 12 40 9 30
Yan Q 2011 [28] 34 34 2 4.8 2 5.7 2 4.8 3 8.6 5 12.2 6 17.1 3 7.3 4 11.4
Li J 2013 [29] 41 35 16 42.1 13 37.1 9 23.7 8 22.8 6 15.8 4 11.4 2 7.1 3 8.5
Lijie H 2014 [30] 38 35 3 10 3 10 3 10 3 10 4 13.3 3 10 6 20 3 10
Miao H 2016 [31] 30 30 4 12.9 5 16.6 11 35.5 10 33.3 24 77.4 20 66.6
  P > 0.05 P > 0.05 P > 0.05 P < 0.05
  1. IL-2 interleukin-2, N, cases; Values are given as number of patients (%). Group 1 = cisplatin+IL-2; Group 2 = cisplatin alone